Blog

$Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research$

Photo of Ira Pastan from federalnewsnetwork.com

Sep 26, 2024, 11:19

Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn:

“BREAKTHROUGH IN TREATMENT: In 2012, Senior Investigator Ira Pastan, M.D., tested the immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia (HCL).

As a result, the drug is now an FDA approved therapy for the disease if it has recurred or progressed after at least two prior systemic therapies.

cancer cancer awareness Cancer research FDA fight against cancer Global fight against cancer Hairy Cell Leukemia HCL Ira Pastan NCI NCI Center for Cancer Research OncoDaily Oncology

Senator Edward Markley in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity